Skip to Content

Protalex Inc PRTX

Rating as of

Morningstar’s Analysis

There is no Morningtar’s Analysis data available.

Company Profile

Business Description

Protalex Inc is a United States-based clinical stage company. It is primarily focused on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases including rheumatoid arthritis and immune thrombocytopenia. The key product candidate of the group is PRTX-100, an immunomodulatory therapy, which is a bacterial protein known to modify aspects of the human immune system. PRTX-100 is effective in animal models of autoimmune diseases and has demonstrated activity on cultured human immune cells at very low concentrations.

131 Columbia Turnpike, Suite 1
Florham Park, NJ, 07932
T +1 215 862-9720
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Aug 31, 2018
Fiscal Year End May 31, 2019
Stock Type Distressed
Employees 2